최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Molecular cancer therapeutics, v.14 no.9, 2015년, pp.2035 - 2048
Ribas, Ricardo (Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom.) , Pancholi, Sunil (Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom.) , Guest, Stephanie K. (Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom.) , Marangoni, Elisabetta (Department of Translational Research, Institut Curie, Paris, France.) , Gao, Qiong (Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom.) , Thuleau, Aurélie (Department of Translational Research, Institut Curie, Paris, France.) , Simigdala, Nikiana (Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom.) , Polanska, Urszula M. (Oncology Innovative Medicines, AstraZeneca, United Kingdom.) , Campbell, Hayley (Oncology Innovative Medicines, AstraZeneca, United Kingdom.) , Rani, Aradhana (Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom.) , Liccardi, Gianmaria (Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom.) , Johnston, Stephen (Royal Marsden Hospital, London, Un) , Davies, Barry R. , Dowsett, Mitch , Martin, Lesley-Ann
PI3K/AKT/mTOR signaling plays an important role in breast cancer. Its interaction with estrogen receptor (ER) signaling becomes more complex and interdependent with acquired endocrine resistance. Targeting mTOR combined with endocrine therapy has shown clinical utility; however, a negative feedback ...
Nat Med Dowsett 8 1341 2002 10.1038/nm1202-1341 Breast cancer: aromatase inhibitors take on tamoxifen
Nature Shaw 441 424 2006 10.1038/nature04869 Ras, PI(3)K and mTOR signalling controls tumour cell growth
Mod Pathol Shoman 18 250 2005 10.1038/modpathol.3800296 Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
Mol Cancer Ther Clark 1 707 2002 Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells
Endocr Relat Cancer Yu 8 249 2001 10.1677/erc.0.0080249 mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
Cancer Res Saal 65 2554 2005 10.1158/0008-5472-CAN-04-3913 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
Nature Simoncini 407 538 2000 10.1038/35035131 Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
J Clin Invest Miller 120 2406 2010 10.1172/JCI41680 Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer
Oncogene Chen 21 4921 2002 10.1038/sj.onc.1205420 Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera
J Biol Chem Campbell 276 9817 2001 10.1074/jbc.M010840200 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance
Science Kato 270 1491 1995 10.1126/science.270.5241.1491 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Biol Reprod Smith 58 627 1998 10.1095/biolreprod58.3.627 Cross-talk between peptide growth factor and estrogen receptor signaling pathways
Mol Cell Biol Bhat-Nakshatri 28 7487 2008 10.1128/MCB.00799-08 AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer
Cancer Res O'Reilly 66 1500 2006 10.1158/0008-5472.CAN-05-2925 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
Cancer Res Sun 65 7052 2005 10.1158/0008-5472.CAN-05-0917 Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
Mol Cancer Ther Davies 11 873 2012 10.1158/1535-7163.MCT-11-0824-T Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background
Breast Cancer Res Fox 15 R55 2013 10.1186/bcr3449 Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation
J Biol Chem Martin 278 30458 2003 10.1074/jbc.M305226200 Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation
Endocr Relat Cancer Pancholi 15 985 2008 10.1677/ERC-07-0240 ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2
Cancer Res Banerjee 69 4716 2009 10.1158/0008-5472.CAN-08-4711 The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase
Adv Enzyme Regul Chou 22 27 1984 10.1016/0065-2571(84)90007-4 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Clin Cancer Res Cottu 20 4314 2014 10.1158/1078-0432.CCR-13-3230 Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts
Nat Rev Cancer Ali 2 101 2002 10.1038/nrc721 Endocrine-responsive breast cancer and strategies for combating resistance
J Biol Chem Stossi 281 16272 2006 10.1074/jbc.M513405200 Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter
Biochem Soc Trans Martinez-Gac 32 360 2004 10.1042/bst0320360 Phosphoinositide 3-kinase and Forkhead, a switch for cell division
Nat Chem Biol Okuzumi 5 484 2009 10.1038/nchembio.183 Inhibitor hijacking of Akt activation
Cell Zha 87 619 1996 10.1016/S0092-8674(00)81382-3 Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)
Sci Transl Med Bosch 7 283ra51 2015 10.1126/scitranslmed.aaa4442 PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
Proc Natl Acad Sci U S A Chakrabarty 109 2718 2012 10.1073/pnas.1018001108 Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
Cancer Cell Chandarlapaty 19 58 2011 10.1016/j.ccr.2010.10.031 AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Cancer Discov Rodrik-Outmezguine 1 248 2011 10.1158/2159-8290.CD-11-0085 mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
Sci Signal Mounir 4 ra62 2011 10.1126/scisignal.2001630 Akt determines cell fate through inhibition of the PERK-eIF2alpha phosphorylation pathway
Biochem J Srinivas 395 653 2006 10.1042/BJ20051794 Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha
Genes Dev Ross-Innes 24 171 2010 10.1101/gad.552910 Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer
Breast Cancer Res Creighton 12 R40 2010 10.1186/bcr2594 Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
Mol Cell Chen 6 127 2000 10.1016/S1097-2765(05)00004-3 Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7
Proc Natl Acad Sci U S A Bour 102 16608 2005 10.1073/pnas.0505556102 Cyclin H binding to the RARalpha activation function (AF)-2 domain directs phosphorylation of the AF-1 domain by cyclin-dependent kinase 7
Nat Commun Johansson 4 2175 2013 10.1038/ncomms3175 Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer
EMBO Rep Nishimoto 7 782 2006 10.1038/sj.embor.7400755 MAPK signalling: ERK5 versus ERK1/2
Oncogene Mongroo 23 8959 2004 10.1038/sj.onc.1208112 Beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer
J Cell Sci Kimura 123 747 2010 10.1242/jcs.052498 Functional molecular imaging of ILK-mediated Akt/PKB signaling cascades and the associated role of beta-parvin
Cell Rep Morfoisse 6 155 2014 10.1016/j.celrep.2013.12.011 Hypoxia induces VEGF-C expression in metastatic tumor cells via a HIF-1alpha-independent translation-mediated mechanism
Cancer Res Balakumaran 69 7803 2009 10.1158/0008-5472.CAN-09-0910 MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.